Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai’s H1 Sales Rise 14.3% on 4 Global Brands, ADC License Income
November 2, 2021
- Shionogi’s H1 Sales Wane 2.3% as Crestor Royalties Almost Disappear
November 2, 2021
- Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
- Eisai’s Medium Molecule E7386 Hits POC, Keytruda Combo Study Now Underway
November 2, 2021
- Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
November 2, 2021
- Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi
November 1, 2021
- Otsuka Files HIF-PH Inhibitor Vadadustat in Europe
November 1, 2021
- Hypertension OK Now in Hand, Novartis Expanding Entresto Pitch to GPs with Superior Efficacy over ARBs
November 1, 2021
- Senju Gearing Up to Grow Lucentis Biosimilar into Its Mainstay Product
November 1, 2021
- Daiichi Sankyo’s 1st Half Operating Profit Jumps 44.9% Thanks to Lixiana, Enhertu
November 1, 2021
- Japan Pharma Market Expected to Log -0.8% to +0.2% Growth through FY2026: IQVIA
October 29, 2021
- Takeda’s H1 Sales Log Two-Digit Growth Driven by Global Brands, FDA Wraps Up Plant Re-Inspection
October 29, 2021
- Takeda to Snap Up UK Cell Therapy Partner GammaDelta
October 29, 2021
- Ono Files Onoact for Pediatric Tachyarrhythmia
October 29, 2021
- Sumitomo Dainippon to Speed Up Development of CNS Blockbuster Hopeful through Otsuka Alliance
October 28, 2021
- Otsuka Collaboration “More Positive” than Solo Even If Profits Shared: Sumitomo Dainippon Chief
October 28, 2021
- Sumitomo Dainippon’s H1 Sales Surge 12.3% on Otsuka Deal
October 28, 2021
- Chugai/TWOCELLS Complete PIII Enrollment for Knee Chondrogenesis Cell Medicine
October 28, 2021
- CNS Alliance with Otsuka Expected to be Long-term: Sumitomo Dainippon Senior Executive
October 28, 2021
- AbbVie Seeks Ulcerous Colitis Indication for Rinvoq in Japan
October 28, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…